Figures computed from official regulatory filings — .
Analysttarget 7.75 USD (+660%) · consensus 4.5/5 · 5 buy · 1 hold · 0 sell
Ownershipinsiders 19.12% · institutions 37.45% · short 15.6% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Coherus Oncology, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
3 buys172 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Ryan Michael Lee | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Newton Charles W. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Satvat Ali J. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Karachun Rita A | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ryan Michael Lee | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Karachun Rita A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Newcomer Lee Nisley | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wahlstrom Matstrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Donnell-Tormey Jill | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Newcomer Lee Nisley | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Satvat Ali J. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Newton Charles W. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Donnell-Tormey Jill | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wahlstrom Matstrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lanfear Dennis M | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| McMichael Bryan J | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| McMichael Bryan J | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lanfear Dennis M | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| McMichael Bryan J | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| McMichael Bryan J | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| McMichael Bryan J | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lanfear Dennis M | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lanfear Dennis M | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lanfear Dennis M | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| McMichael Bryan J | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |